Institutional investors purchased a net $476.3 thousand shares of HALO during the quarter ended December 2015. This may signal that the smart money is gaining interest in this company as the 62.38% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
VIRTUS INVESTMENT ADVISERS, INC. Bought 56.1 Thousand shares of Halozyme Therapeutics Inc
CREATIVE PLANNING, INC. Bought 46.0 Thousand shares of Halozyme Therapeutics Inc